The brief

Analyst view

• Publicly traded on Nasdaq (BNTX); 7,269 employees as of March 2026. Full-year 2025 revenue: €2.87 billion.
• June 2025 BMS partnership: $1.5B upfront + $2B non-contingent + up to $7.6B in milestones for BNT327.
• June 2025: Acquired CureVac for $1.25 billion to expand mRNA oncology pipeline.

Technical approach

As reported

Personalized mRNA

Patient-matched tumor vaccines

Designs mRNA matched to each patient's tumor mutations, manufactured quickly for cancer immunotherapy.

Bispecific antibodies

Dual-target checkpoint + angiogenesis

BNT327 blocks both PD-L1 (immune checkpoint) and VEGF (tumor blood supply) on one molecule.

FixVac platform

Off-the-shelf vaccines

Fixed-sequence mRNA vaccines for many patients, reducing cost and manufacturing complexity.